Agenda - Main Conference Day 1 - Oct 21, 2025 | Antibody Engineering & Therapeutics Asia

08:00 - 08:25

Registration and Coffee

08:25 - 08:30

Chairperson’s Remarks

Keynote Presentations

Showing 1 of 1 Streams

Keynote Presentations

08:30 - 09:00

Sequential Drug Discovery Utilizing Proprietary Antibody Engineering Technology

Tomoyuki Igawa, PhD - Vice President, Head of Discovery Research, Chugai Pharmaceutical Co., Ltd.

09:00 - 09:30

Developing a Pipeline Using FcRn Biology for Degradation of Pathogenic Antibodies

Karen Silence, PhD - Head Preclinical Product Development, Argenx

09:30 - 10:00

Late Breaking Keynote

10:00 - 10:45

Networking Refreshment Break with Exhibit and Poster Viewing

Innovation in Antibody Discovery, Technology & Engineering

Showing 1 of 1 Streams

Innovation in Antibody Discovery, Technology & Engineering

10:45 - 11:15

Innovative Approaches in Antibody Display Selections: Advancing Therapeutic Discovery

Fortunato Ferrara, PhD - Vice President, Antibody Discovery, Specifica

11:15 - 11:45

Human Antibody Discovery and Engineering: The Adimab Way

This presentation will explore how Adimab has revolutionized antibody discovery, growing from an innovative startup into a leading platform technology company. We will examine key technological breakthroughs in our platform, focusing on synthetic antibody library evolution, advances in multispecific generation, and novel approaches to developability optimization. Join us to learn how Adimab's engineering-driven approach is shaping the future of therapeutics.

Aaron Sato, PhD - Chief Strategy Officer, Adimab

11:45 - 12:15

Molecular Projection, An Accelerator for 3D Image-based Modality and Functional Design to Improve the Engineering of Biopharmaceuticals Spanning Formulation and Quality Control Based on EDT Observation in Solution

Takashi Sato, PhD - Chief Scientist & Technical Architect, Life Science Product Division, Rigaku Corporation

12:15 - 12:45

Asian Antibody Company Short Spotlight/Pipeline Presentations

For more information about presenting in this session, please contact Michael Keenan at Michael.Keenan@informa.com

12:45 - 13:55

Networking Luncheon with Exhibit and Poster Viewing

Novel Antibody Formats and Scaffolds

Showing 1 of 1 Streams

Novel Antibody Formats and Scaffolds

13:55 - 14:00

Chairperson's Remarks

14:00 - 14:30

The Therapeutic Potential of IgE and IgE-derived Antibodies

Kevin Fitzgerald, PhD. - Chief Scientific Officer, Epsilogen

14:30 - 15:00

Broad Epitope Coverage from Human Immune Repertoires Produced in Divergent Host Species, Including Alternative Antibody Scaffolds for Building Multi-specifics

Yasmina Abdiche, PhD - SVP, Exploratory Research, OmniAb

15:00 - 15:30

Humanized scFv Antibody Specific to an Extracellular Epitope of P2X4R as Therapy for Chronic Pain Management

Adinarayana Kunamneni, PhD - Associate Professor of Medicine, Mayo Clinic

15:30 - 16:30

Networking Refreshment Break with Exhibit and Poster Viewing

Bispecifics and Multispecifics

Showing 1 of 1 Streams

Bispecifics and Multispecifics

16:30 - 17:00

MabPair Platfom- An Innovative Approach to Develop Antibody Combination Therapy

Wei Yan, PhD - CEO, Sound Biologics

17:00 - 17:30

KK2260, A Novel Bispecific Antibody Targeting EGFR and TfR1 with Unique TfR1 Degradation Mechanism, Demonstrates Antitumor Effect in EGFR-expressing Tumors

Keisuke Mitamura - Senior Scientist, Research Division, Kyowa Kirin

17:30 - 18:00

Asian Antibody Company Short Spotlight/Pipeline Presentations

For more information about presenting in this session, please contact Michael Keenan at Michael.Keenan@informa.com

18:00 - 19:00

Networking Cocktail Reception with Exhibit and Poster Viewing

Main Conference Day 1 - Oct 21, 2025Tuesday, 21 October 2025 - JT (Japan Time, GMT+09:00)

Get the Latest Event Updates